|
1
|
Huse JT, Holland E and DeAngelis LM:
Glioblastoma: Molecular analysis and clinical implications. Annu
Rev Med. 64:59–70. 2013. View Article : Google Scholar
|
|
2
|
Tanase CP, Enciu AM, Mihai S, Neagu AI,
Calenic B and Cruceru ML: Anti-cancer therapies in high grade
gliomas. Curr Proteomics. 10:246–260. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Omuro A and DeAngelis LM: Glioblastoma and
other malignant gliomas: A clinical review. JAMA. 310:1842–1850.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Thomas RP, Recht L and Nagpal S: Advances
in the management of glioblastoma: The role of temozolomide and
MGMT testing. Clin Pharmacol. 5:1–9. 2013.PubMed/NCBI
|
|
5
|
Fiorentino A, Chiumento C, Caivano R,
Cozzolino M, Pedicini P and Fusco V: Adjuvant radiochemotherapy in
the elderly affected by glioblastoma: Single-institution experience
and literature review. Radiol Med. 118:870–881. 2013.In Italian.
View Article : Google Scholar
|
|
6
|
Sengupta S, Marrinan J, Frishman C and
Sampath P: Impact of temozolomide on immune response during
malignant glioma chemotherapy. Clin Dev Immunol. 2012:8310902012.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Chamberlain MC: Temozolomide: Therapeutic
limitations in the treatment of adult high-grade gliomas. Expert
Rev Neurother. 10:1537–1544. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Jiang G, Wei ZP, Pei DS, Xin Y, Liu YQ and
Zheng JN: A novel approach to overcome temozolomide resistance in
glioma and melanoma: Inactivation of MGMT by gene therapy. Biochem
Biophys Res Commun. 406:311–314. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Vander Heiden MG, Cantley LC and Thompson
CB: Understanding the Warburg effect: The metabolic requirements of
cell proliferation. Science. 324:1029–1033. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Zhao Y, Butler EB and Tan M: Targeting
cellular metabolism to improve cancer therapeutics. Cell Death Dis.
4:e5322013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhou M, Zhao Y, Ding Y, Liu H, Liu Z,
Fodstad O, Riker AI, Kamarajugadda S, Lu J, Owen LB, et al: Warburg
effect in chemosensitivity: Targeting lactate dehydrogenase-A
re-sensitizes taxol-resistant cancer cells to taxol. Mol Cancer.
9:332010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Pan Q, Yang XJ, Wang HM, Dong XT, Wang W,
Li Y and Li JM: Chemoresistance to temozolomide in human glioma
cell line U251 is associated with increased activity of
O6-methylguanine-DNA methyltransferase and can be overcome by
metronomic temo-zolomide regimen. Cell Biochem Biophys. 62:185–191.
2012. View Article : Google Scholar
|
|
13
|
Oliva CR, Moellering DR, Gillespie GY and
Griguer CE: Acquisition of chemoresistance in gliomas is associated
with increased mitochondrial coupling and decreased ROS production.
PLoS One. 6:e246652011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Fujiwara S, Kawano Y, Yuki H, Okuno Y,
Nosaka K, Mitsuya H and Hata H: PDK1 inhibition is a novel
therapeutic target in multiple myeloma. Br J Cancer. 108:170–178.
2013.PubMed/NCBI
|
|
15
|
Shin YK, Yoo BC, Hong YS, Chang HJ, Jung
KH, Jeong SY and Park JG: Upregulation of glycolytic enzymes in
proteins secreted from human colon cancer cells with 5-fluorouracil
resistance. Electrophoresis. 30:2182–2192. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yusuf RZ, Duan Z, Lamendola DE, Penson RT
and Seiden MV: Paclitaxel resistance: Molecular mechanisms and
pharmacologic manipulation. Curr Cancer Drug Targets. 3:1–19. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Orr GA, Verdier-Pinard P, McDaid H and
Horwitz SB: Mechanisms of Taxol resistance related to microtubules.
Oncogene. 22:7280–7295. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Donnenberg VS and Donnenberg AD: Multiple
drug resistance in cancer revisited: The cancer stem cell
hypothesis. J Clin Pharmacol. 45:872–877. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kavallaris M, Kuo DY, Burkhart CA, Regl
DL, Norris MD, Haber M and Horwitz SB: Taxol-resistant epithelial
ovarian tumors are associated with altered expression of specific
beta-tubulin isotypes. J Clin Invest. 100:1282–1293. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Tan M, Jing T, Lan KH, Neal CL, Li P, Lee
S, Fang D, Nagata Y, Liu J, Arlinghaus R, et al: Phosphorylation on
tyrosine-15 of p34(Cdc2) by ErbB2 inhibits p34(Cdc2) activation and
is involved in resistance to taxol-induced apoptosis. Mol Cell.
9:993–1004. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Martello LA, Verdier-Pinard P, Shen HJ, He
L, Torres K, Orr GA and Horwitz SB: Elevated levels of microtubule
destabilizing factors in a Taxol-resistant/dependent A549 cell line
with an alpha-tubulin mutation. Cancer Res. 63:1207–1213.
2003.PubMed/NCBI
|
|
22
|
Panda D, Miller HP, Banerjee A, Ludueña RF
and Wilson L: Microtubule dynamics in vitro are regulated by the
tubulin isotype composition. Proc Natl Acad Sci USA.
91:11358–11362. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Lai D, Ho KC, Hao Y and Yang X: Taxol
resistance in breast cancer cells is mediated by the hippo pathway
component TAZ and its downstream transcriptional targets Cyr61 and
CTGF. Cancer Res. 71:2728–2738. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Li Y, Tang K, Zhang H, Zhang Y, Zhou W and
Chen X: Function of Aurora kinase A in Taxol-resistant breast
cancer and its correlation with P-gp. Mol Med Rep. 4:739–746.
2011.PubMed/NCBI
|
|
25
|
Tong J, Xie G, He J, Li J, Pan F and Liang
H: Synergistic antitumor effect of dichloroacetate in combination
with 5-fluorouracil in colorectal cancer. J Biomed Biotechnol.
2011:7405642011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Guo W, Zhang Y, Chen T, Wang Y, Xue J,
Zhang Y, Xiao W, Mo X and Lu Y: Efficacy of RNAi targeting of
pyruvate kinase M2 combined with cisplatin in a lung cancer model.
J Cancer Res Clin Oncol. 137:65–72. 2011. View Article : Google Scholar
|
|
27
|
Cao X, Fang L, Gibbs S, Huang Y, Dai Z,
Wen P, Zheng X, Sadee W and Sun D: Glucose uptake inhibitor
sensitizes cancer cells to daunorubicin and overcomes drug
resistance in hypoxia. Cancer Chemother Pharmacol. 59:495–505.
2007. View Article : Google Scholar
|
|
28
|
Liu Y, Cao Y, Zhang W, Bergmeier S, Qian
Y, Akbar H, Colvin R, Ding J, Tong L, Wu S, et al: A small-molecule
inhibitor of glucose transporter 1 downregulates glycolysis,
induces cell-cycle arrest, and inhibits cancer cell growth in vitro
and in vivo. Mol Cancer Ther. 11:1672–1682. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Zhao Y, Liu H, Liu Z, Ding Y, Ledoux SP,
Wilson GL, Voellmy R, Lin Y, Lin W, Nahta R, et al: Overcoming
trastuzumab resistance in breast cancer by targeting dysregulated
glucose metabolism. Cancer Res. 71:4585–4597. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Nakano A, Tsuji D, Miki H, Cui Q, El Sayed
SM, Ikegame A, Oda A, Amou H, Nakamura S, Harada T, et al:
Glycolysis inhibition inactivates ABC transporters to restore drug
sensitivity in malignant cells. PLoS One. 6:e272222011. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Hadzic T, Aykin-Burns N, Zhu Y, Coleman
MC, Leick K, Jacobson GM and Spitz DR: Paclitaxel combined with
inhibitors of glucose and hydroperoxide metabolism enhances breast
cancer cell killing via H2O2-mediated
oxidative stress. Free Radic Biol Med. 48:1024–1033. 2010.
View Article : Google Scholar : PubMed/NCBI
|
